Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer That Overexpresses HER2
PHASE2CompletedINTERVENTIONAL
Enrollment
84
Participants
Timeline
Start Date
February 29, 2000
Primary Completion Date
August 31, 2005
Conditions
Recurrent Non-small Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung Cancer
Interventions
BIOLOGICAL
trastuzumab
Given IV
OTHER
laboratory biomarker analysis
Correlative studies
Trial Locations (1)
60606
Cancer and Leukemia Group B, Chicago
All Listed Sponsors
lead
National Cancer Institute (NCI)
NIH
NCT00004883 - Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer That Overexpresses HER2 | Biotech Hunter | Biotech Hunter